Health Care Cost

A review of therapies for atopic dermatitis (AD) found adequate net health benefit for new treatments. However, safety remains a concern for the Janus kinase (JAK) inhibitors.

Vizient recently released its Summer 2021 Pharmacy Market Outlook, which projects pharmaceutical spending for 2022 based on an analysis of its members' data. On this episode of Managed Care Cast, we talk about some of the findings.

The analysis included 64 cost-effectiveness analysis scenarios across more than 30 studies between 2009 and 2019, approximately half (53%) of which determined precision diagnostic testing to be cost-effective.

Using artificial intelligence (AI) effectively may help to revolutionize the diagnosis, monitoring, and treatment of multiple sclerosis (MS), as well as optimizing understanding of the immune-mediated disease.

The combined toll of the COVID-19 pandemic and the health effects of climate change tests an already beleaguered US health system.

FDA reportedly aims to fully approve Pfizer-BioNTech COVID-19 vaccine by early next month; Biogen’s Alzheimer drug sees little uptake; majority of Americans over 65 have received at least 1 dose of a COVID-19 vaccine.

The study was conducted to shed more light on the growing issue of polypharmacy, an issue that is expected to increase as the US population ages.

On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.

In this episode of Managed Care Cast, the lead author of an article in the July issue of The American Journal of Managed Care describes the latest research that looks at the power of self-insured employers to negotiate hospital prices and the relationship between employer market power and hospital prices.

A string of controversies surrounding the approval of Biogen's Alzheimer disease drug aducanumab (Aduhelm) has not only called into question the independent nature of the FDA, but puts both providers and patients in a challenging position when it comes to deciding whether or not to prescribe or take the treatment.

Not all asthma is created equal, nor will all therapies work for all patients. With continued innovations in asthma treatments offering new, improved options for patients, we are more prepared than ever to address uncontrolled asthma head-on.

The measure is designed to end surprise medical billing and balance billing, taking the first step to implement the so-called No Surprises Act that passed Congress at the end of last year.

With systemic health and social inequalities contributing to a lack of health care access and a growing mortality risk among rural Americans, the COVID-19 pandemic has further exacerbated health issues present between community lines. We spotlight several health challenges in these communities and potential solutions to improve the general health of rural populations.

The head of AHIP sat down with a senator and 3 health care executives for a conversation about payment and access issues at the organization's 2021 Institute and Expo Online.

A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.

HHS Secretary Xavier Becerra and CMS Administrator Chiquita Brooks-LaSure discussed next steps following the Supreme Court’s decision to uphold the Affordable Care Act (ACA), including continued expansion of Medicaid benefit coverage and addressing disparities in maternal mortality rates nationwide.

In a 7 to 2 decision, the Supreme Court ruled Thursday that the Affordable Care Act (ACA) will stand, as plaintiffs seeking to declare the law unconstitutional did not have standing.

On this episode of Managed Care Cast, we speak with the author of the annual PwC Behind the Numbers report, which looks ahead at medical cost trends in the United States.

Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.

A new study from Milliman investigated the potential financial impact if H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act, was fully implemented.

United States to buy and donate 500 million COVID-19 vaccine doses to the world; an FDA advisor resigns over a controversial Alzheimer drug approval; Nevada becomes the second state to offer state-managed health insurance plans.

FDA and ASPR issue policy recommendations to reform US pharmaceutical supply chains; insurer coverage implications of the newly approved therapy in Alzheimer disease; Apple announces new health data sharing features.

The researchers created a model that simulated what would happen when health systems and providers began working together in Medicare accountable care organizations (ACOs) in arrangements that did not extend to outright mergers or acquisitions.

The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.

Davey Daniel, MD, hematology/medical oncology specialist, Tennessee Oncology, discusses findings of an abstract presented at ASCO 2021 showing a lower total cost of care paid by Medicare for episodes of care for patients in the Oncology Care Model (OCM) enrolled in clinical trials vs those receiving routine care.

Stakeholders discuss barriers and solutions to employer engagement on value assessment, which includes redefining goals to that of the employer and patient, and moving beyond the scope of cost and clinical outcomes.

As patients with chronic myeloid leukemia (CML) fail on treatment and move to later lines of therapy, the impact on their health-related quality of life and the economic burden significantly increase.

As awareness of nonalcoholic fatty liver disease (NAFLD) rises, it is essential to develop and implement a rigorously determined approach to identify patients who will, or will not, benefit from diagnostic evaluation.

Deploying vibration-controlled transient elastography/controlled attenuation parameter devices at the population level is a financially advantageous solution to address the epidemic of fatty liver disease.